April 20, 2023
Taiho Pharmaceutical said on April 19 that the US FDA has accepted for priority review its application for its cancer drug Lonsurf (trifluridine + tipiracil) in combination with bevacizumab for the treatment of certain patients with advanced colorectal cancer. The...read more